Search

Displaying results 921 - 930 of 2817 in total
  1. Drug

    PF-03814735

    go.drugbank.com/drugs/DB13059
    Investigational

    PF-03814735 has been used in trials studying the treatment of Solid Tumors.

  2. Drug

    Albutrepenonacog alfa

    go.drugbank.com/drugs/DB13884
    Approved

    Albutrepenonacog alfa (rIX-RFP) is a recombinant fusion protein that links a recombinant coagulation factor IX (rFIX) with a recombinant human albumin (rAlbumin). It was developed by CSL Behring Canada, Inc and approved by Health Canada ...

  3. Drug

    Pf-04531083

    go.drugbank.com/drugs/DB12468
    Investigational

    Pf-04531083 has been investigated for the treatment of Pain and Chronic Pain.

  4. Drug

    PF-06835919

    go.drugbank.com/drugs/DB19163
    Investigational

    PF-06835919 is under investigation in clinical trial NCT05463575 (Ketohexokinase Inhibition in NAFLD).

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C8 Substrates
  5. Drug

    PD-217014

    go.drugbank.com/drugs/DB12493
    Investigational

    PD-217,014 has been used in trials studying the treatment of Pain and Irritable Bowel Syndrome.

  6. Drug

    LB-P8

    go.drugbank.com/drugs/DB18535
    Investigational

    LB-P8 is an investigational live biotherapeutic product consisting of a single bacterial strain (_Leuconostoc citreum_).

  7. Drug

    Calcipotriol

    go.drugbank.com/drugs/DB02300
    ApprovedInvestigational

    Calcipotriol (INN) or calcipotriene (USAN) is a sythetic derivative of calcitriol or Vitamin D.

    Mixtures: Dovobet Gel, Xamiol Gel
  8. Drug

    Vadadustat

    go.drugbank.com/drugs/DB12255
    ApprovedInvestigational

    [A244165] A relatively new and alternative treatment option for patients with anemia associated with CKD is the use of small molecule inhibitors of hypoxia-inducible factor prolyl-hydroxylase (HIF-PH … [A244165] Vadadustat is an orally administered inhibitor of HIF-PH with a safety and efficacy profile non-inferior to [darbepoetin alfa] for the treatment of anemia in patients with CKD undergoing dialysis

    Categories: Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 Enzyme Inducers
  9. Drug

    Depemokimab

    go.drugbank.com/drugs/DB18846
    ApprovedInvestigational

    Depemokimab is a humanized Immunoglobulin G1 (IgG1) monoclonal antibody and a long-acting drug. Its long duration of action is granted by seven amino acid substitutions in the heavy chain sequence. Depemokimab blocks interleukin-5 (IL-5)...

  10. Drug

    Blinatumomab

    go.drugbank.com/drugs/DB09052
    ApprovedInvestigational

    [A7659,A7660,A254831] Blinatumomab is manufactured by Amgen Inc. and marketed under the brand Blincyto.